Down-regulation of ALKBH2 increases cisplatin sensitivity in H1299 lung cancer cells |
| |
Authors: | Wu Shuang-shuang Xu Wei Liu Shan Chen Bo Wang Xue-li Wang Yan Liu Shi-feng Wu Jian-qing |
| |
Institution: | Department of Geriatrics, the First Affiliated Hospital of Nanjing Medical University, China. |
| |
Abstract: | Aim:To elucidate the combined effect of alkylated DNA repair protein alkB homolog 2 (ALKBH2)-targeting gene therapy and cisplatin (cDDP) chemotherapy on the non-small cell lung cancer (NSCLC) H1299 cell line.Methods:ALKBH2 was down-regulated in H1299 cells by lentivirus-mediated RNA interference (RNAi). Changes in ALKBH2 expression were determined using real-time RT-PCR and Western blotting. Cell viability was evaluated using MTT assay. DNA synthesis in proliferating cells was determined using BrdU incorporation assay. Cell apoptosis was determined using flow cytometry.Results:Lentivirus-mediated ALKBH2 silencing alone did not induce apoptosis or attenuate the growth potential of H1299 cells within five days post-infection. Combined treatment modalities with lentivirus-mediated ALKBH2 down-regulation and cDDP (333 μmol/L) were significantly more potent in inhibiting cell growth and inducing apoptosis than mono-chemotherapy.Conclusion:Combined treatment modalities of ALKBH2 knockdown and cDDP chemotherapy have the potential to improve the efficacy in the treatment of NSCLC. |
| |
Keywords: | lentivirus RNA interference alkB homolog 2 cisplatin non-small cell lung cancer |
本文献已被 PubMed 等数据库收录! |